Zelgen Biopharmaceuticals (688266.SH) Receives $10 Million Milestone Payment from AbbVie for ZG006
Zelgen Biopharmaceuticals (688266.SH) announced that on December 30, 2025, the company entered into a strategic collaboration and license option agreement with AbbVie Group Holdings Ltd. (registered in Bermuda) (referred to as "AbbVie") for the global development and commercialization of ZG006 (Alveltamig). Following the execution of the agreement, the company and AbbVie have actively advanced the subsequent development of ZG006. The company received the US$100 million upfront payment from AbbVie earlier this year in accordance with the timeline stipulated in the agreement, and recently received a US$10 million near-term milestone payment from AbbVie based on clinical trial progress.
Zelgen Biopharmaceuticals (688266.SH) announced that on December 30, 2025, the company entered into a strategic collaboration and license option agreement with AbbVie Group Holdings Ltd. (registered in Bermuda) (referred to as "AbbVie") for the global development and commercialization of ZG006 (Alveltamig). Following the execution of the agreement, the company and AbbVie have actively advanced the subsequent development of ZG006. The company received the US$100 million upfront payment from AbbVie at the beginning of the year in accordance with the timeline stipulated in the agreement, and recently received a US$10 million near-term milestone payment from AbbVie based on clinical trial progress.
Related Articles
Q TECH (01478) Chairman enters into several European-style put option contracts involving 5.58864 million shares of the Company
US Stock Market Move | Cloud computing service provider concept stocks broadly declined; IREN Ltd (IREN.US) fell nearly 6%.
DIAGENS-B(02526) grants a total of 779,000 share awards
Q TECH (01478) Chairman enters into several European-style put option contracts involving 5.58864 million shares of the Company
US Stock Market Move | Cloud computing service provider concept stocks broadly declined; IREN Ltd (IREN.US) fell nearly 6%.
DIAGENS-B(02526) grants a total of 779,000 share awards
